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Introduction
Community pharmacies are a dynamic environment with pro-
fessionals who are keen to provide care and support for a wide 
range of healthcare service users. There are around 11,600 
community pharmacies in England, and 89% of the popula-
tion are able to reach such facilities within a 20-minute walk1, 
allowing pharmacies to be at the core of communities and 
patient care. Over time, the role of a community pharmacist has 
expanded beyond the traditional dispensing duties2, includ-
ing taking on wider public health roles and research activities. 
Research in this setting is, however, not without its challenges, 
with time constraints and remuneration3 having been reported 
as difficulties previously. More widely, difficulties in retain-
ing research participants recruited to trials is a common issue 
and represents a significant risk to the statistical power and 
analysis of trial results4.
The CHAMP-1 (Community pharmacy: Highlighting Alcohol 
use in Medication aPpointments) pilot cluster trial is part of a 
programme of work which aims to collaborate with the phar-
macy profession and patients, to produce an intervention discuss-
ing alcohol within routine medication consultations. The design 
of the trial was informed by pre-trial studies conducted by the 
CHAMP-1 research team, including observational and inter-
view work with patients and pharmacists5,6. Outcome data 
collection in the trial provided a challenge as participants were 
recruited by their community pharmacist but followed-up by 
a trained researcher who the participant had no prior contact 
with. Full results of the pilot trial will be reported elsewhere. 
This paper focuses specifically on our experiences of contacting 
participants and the techniques used in an attempt to maximise 
our follow-up rate.
Methods
Ethical approval for the CHAMP-1 pilot trial was provided 
by South West - Frenchay Research Ethics Committee 
(19/SW/0082). The trial was registered with the ISRCTN registry 
(ISRCTN57447996) on 17th June 2019. All participants provided 
written informed consent to participate in the trial as described 
in the Participant Information Sheet7.
At least four clusters per arm are recommended for clus-
ter pilot randomised, controlled trials8. Assuming an average 
of eight participants per pharmacy are recruited, we planned 
to recruit 80 participants from 10 successfully recruiting 
pharmacies (equivalent to 70 participants in an individually ran-
domised trial, assuming an intracluster correlation coefficient 
(ICC) 0.02). A trial of this size will allow a completion rate 
of 80% to be estimated within a 95% confidence interval 
of ±9%9. If we identify 160 eligible subjects, then we will 
be able to estimate a participation rate of 50% to within a 95% 
confidence interval of ±8%.
Randomisation for the pilot trial was undertaken by an inde-
pendent York Trials Unit statistician using minimisation. Mini-
misation was undertaken in minimPy using naïve minimisation 
with base probability 1.0 (i.e. deterministic minimisation) using 
marginal balance as the distance measure and with minimisa-
tion factors having a weighting of 1. Randomisation was at the 
level of the community pharmacy (with one practitioner per 
pharmacy). A separate randomisation sequence investigating 
the methodological feasibility of sending text messages to 
participants and their effect on retention was generated using 
block randomisation stratified by pharmacy.
Analyses for the pilot trial were conducted in R (R Devel-
opment Core Team and R Core Team, 2011) following the 
principles of intention-to-treat with participant outcomes 
analysed according to their original, randomised group, where 
data are available, irrespective of deviations based on non- 
compliance. Analyses regarding the text message aspect of the 
trial were conducted in Microsoft Excel (2016).
Twenty-seven community pharmacies in Yorkshire, England 
expressed an interest to be involved in the pilot trial, of which 
four were excluded (two had previous CHAMP-1 involvement 
and two did not respond) and 23 were assessed for eligibil-
ity. Of these, two were found to be ineligible and 11 were 
excluded for varying reasons. Ten pharmacies were deemed to 
be eligible and were randomised to conduct their Medicine Use 
Review (MUR) or New Medicine Service (NMS) consultations 
as usual (control), or to incorporate the Medicines and Alco-
hol Consultation (MAC) intervention. Five pharmacies were 
randomised to the control group, and five were randomised to 
provide the intervention. The median cluster size was five in 
the control arm, and four in the intervention arm. One phar-
macist from each of the pharmacies received training in the 
recruitment and study procedures for the trial; with those 
randomised to the intervention arm receiving additional train-
ing on the MAC. The MAC intervention is intended to help 
patients to think through whether drinking alcohol affects 
their medication use, the conditions for which they are 
prescribed, and their health more broadly; and to enable phar-
macists to skilfully engage with these issues in a person-centred 
manner. The intervention involved pharmacists attending two 
practice development training days; using a MAC guide which 
summarised the structure of the intervention and core content 
within medication consultations; engaging with a range of 
learning support resources; receiving individually tailored 
weekly practice development support site visits or telephone 
calls by the MAC support team; and an invitation to engage 
in peer support.
Participant recruitment was conducted by community phar-
macists, and patients were eligible for the trial if they were 
aged 18 and over, attending for a MUR or NMS consultation 
with their pharmacist, and drinking alcohol at least twice per 
week. Patients were excluded from the trial if they had received 
alcohol treatment in the past 12 months.
All participants were followed-up with a telephone call from 
a trained researcher two months after entering the trial and 
having their consultation with the pharmacist. During the 
telephone call, the trained researcher collected outcome data 
using a Case Report Form. The research team considered the 
potential challenges to successful follow-up based on pre-trial 
feasibility work, such as the two month time lapse between 
the consultation and follow-up call, and the willingness of 
3DJHRI
)5HVHDUFK/DVWXSGDWHG$8*
participants to speak about their health and wellbeing to some-
one they did not know. To facilitate trial follow-up, the study 
team established various procedures to address these such as: 
asking participants for more than one telephone number if 
available (e.g. a landline and mobile telephone number); ask-
ing for the participant’s preferred days and times for contact; 
sending a text message to remind them that a researcher would 
be contacting them in the near future to conduct their follow-up 
telephone call; attempting to contact participants three times 
before sending the follow-up questionnaire7 (the same form 
as that completed by telephone) by post; calling from one 
single telephone number to enable participants to recognise the 
number if they were unable to be contacted at the first attempt; 
and leaving voicemail messages where possible requesting 
that participants return the call. Participants who completed 
follow-up were given a £10 ‘thank you’ gift card. This was 
explained in the patient information sheet7 provided during 
recruitment and mentioned early in the conversation during 
the follow-up telephone call.
Results
The CHAMP-1 pilot trial recruited 51 participants from 10 
pharmacies. Of these, 55% were men and 45% were women7. 
The mean age of those involved was 66.5 years. Forty-seven 
(92%) participants were successfully followed up at two 
months. Thirty-eight (81%) of the 47 responses were provided 
by telephone and nine (19%) participants completed the fol-
low-up questionnaire after being sent it by post, having not 
responded to the telephone calls. Four participants did not respond 
to the telephone calls or return the follow-up questionnaire 
by post and therefore their outcome data was not collected.
All participants provided at least one telephone number and 
34 (67%) participants provided a mobile telephone number, 
and therefore were possibly more likely to be contactable 
if they were not at the location of their landline telephone. 
Forty-eight participants (94%) also consented to receiving 
a text message that would remind them about the follow-up 
telephone call; however, of these, 15 (31%) did not provide 
a mobile number to enable this to occur. Due to technical 
difficulties, only seven of the text messages were sent as planned.
Of the 38 follow-up calls completed by telephone, 17 (45%) 
participants were successfully reached at the first attempt 
of contact by the trained researcher; 16 (42%) at the second 
attempt; and five (13%) at the third attempt. If no contact had 
been made after the third attempt, the follow-up questionnaire, 
which was the same as that completed by telephone, was posted 
to the participant. Having made contact, nine of the partici-
pants requested that the follow-up call be arranged for a more 
convenient time and this was scheduled accordingly. Eight 
of these calls were completed successfully as arranged, with 
five participants requesting this at the first attempt at contact, 
and three asking during the second. The ninth participant 
arranged their follow-up call after one attempt at contact; 
however, they did not engage with the re-arranged or subsequent 
telephone calls, and their data collection was completed 
by post.
Discussion/conclusions
The trial involved participants with a range of ages and medi-
cal conditions and therefore is broadly representative of the 
type of patients that use community pharmacies. Whilst this 
was a small pilot cluster trial, it describes the initiatives used to 
encourage a successful follow-up rate in potentially challenging 
circumstances. The results suggest that patients recruited 
within community pharmacies are willing to complete further 
data collection activities which do not involve their pharmacy 
or pharmacist. Repeated efforts to make contact were required 
for over half of participants.
It is important to ensure that all necessary information is 
collected whilst completing recruitment procedures, as approxi-
mately a third of participants consented to receive a text 
message reminder about their follow-up telephone call, however 
did not provide a mobile number for this to be sent to.
Future research is needed with larger samples and longer 
follow-up periods to examine other potential mechanisms that 
contribute to successful follow-up of trial participants recruited 
in this clinical setting.
Data availability
Underlying data
Open Science Framework: CHAMP-1 Pilot Retention Data. 
https://doi.org/10.17605/OSF.IO/KCPHQ7.
This project contains the following underlying data:
-   CHAMP-1 Pilot Retention Data.csv
-   Participant demographic data.csv
Extended data
Open Science Framework: CHAMP-1 Pilot Retention Data. 
https://doi.org/10.17605/OSF.IO/KCPHQ7.
This project contains the following extended data:
-    CHAMP1_FUpLong_v2 (49582 – Activated, VersiForm)_
Reference.pdf (follow-up questionnaire)
-    CHAMP1_FUpShort_v2 (13283 – Activated, VersiForm)_
Reference.pdf (follow-up questionnaire)
-    REFERENCE 2A CHAMP-1 Pilot Patient Consent Form 
Version 2.0 07.05.2019.pdf
-    REFERENCE 2A CHAMP-1 Pilot Patient Information 
Sheet Version 2.0 07.05.2019.pdf
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
3DJHRI
)5HVHDUFK/DVWXSGDWHG$8*
References
1. Committee BMAGP and Committee PSN: The community pharmacy  a guide 
IRUJHQHUDOSUDFWLWLRQHUVDQGSUDFWLFHVWDࢆ BMA and PSNC. 2019.   
Reference Source
2. Sabater-Galindo M, de Maya SR, Benrimoj SI, et al.: Patients expectations 
of the role of the community pharmacist: Development and testing of a 
FRQFHSWXDOPRGHO Res Social Adm Pharm. 2017; 13(2): 313320.  
PubMed Abstract | Publisher Full Text 
3. Crilly P, Patel N, Ogunrinde A, et al.: Community pharmacists involvement in 
UHVHDUFKLQWKH8QLWHG.LQJGRP Pharmacy (Basel). 2017; 5: 48.  
PubMed Abstract | Publisher Full Text | Free Full Text 
4. Kearney A, Daykin A, Shaw ARG, et al.: Identifying research priorities for 
HࢆHFWLYHUHWHQWLRQVWUDWHJLHVLQFOLQLFDOWULDOV Trials. 2017; 18(1): 406. 
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Madden M, Morris S, Atkin K, et al.: Patient perspectives on discussing 
DOFRKRODVSDUWRIPHGLFLQHVUHYLHZLQFRPPXQLW\SKDUPDFLHV  
Res Soc Admin Pharm. 2020; 16(1): 96101.  
PubMed Abstract | Publisher Full Text 
6. Morris S, Madden M, Gough B, et al.: Missing in action: Insights from an 
exploratory ethnographic observation study of alcohol in everyday UK 
FRPPXQLW\SKDUPDF\SUDFWLFH Drug Alcohol Rev. 2019; 38(5): 561568. 
PubMed Abstract | Publisher Full Text 
7. Watson M: &+$033LORW5HWHQWLRQ'DWD OSF. 2020.  
KWWSZZZGRLRUJ26),2.&3+Q
8. Hayes RJ, Moulton LH: &OXVWHUUDQGRPLVHGWULDOV CRC press, 2017.  
Publisher Full Text 
9. Hertzog MA: &RQVLGHUDWLRQVLQGHWHUPLQLQJVDPSOHVL]HIRUSLORWVWXGLHV 
Res Nurs Health. 2008; 31(2): 180191.  
PubMed Abstract |Publisher Full Text 
3DJHRI
)5HVHDUFK/DVWXSGDWHG$8*
7KHEHQHILWVRISXEOLVKLQJZLWK)5HVHDUFK
<RXUDUWLFOHLVSXEOLVKHGZLWKLQGD\VZLWKQRHGLWRULDOELDVȎ
<RXFDQSXEOLVKWUDGLWLRQDODUWLFOHVQXOOQHJDWLYHUHVXOWVFDVHUHSRUWVGDWDQRWHVDQGPRUHȎ
7KHSHHUUHYLHZSURFHVVLVWUDQVSDUHQWDQGFROODERUDWLYHȎ
<RXUDUWLFOHLVLQGH[HGLQ3XE0HGDIWHUSDVVLQJSHHUUHYLHZȎ
'HGLFDWHGFXVWRPHUVXSSRUWDWHYHU\VWDJHȎ
)RUSUHVXEPLVVLRQHQTXLULHVFRQWDFWUHVHDUFK#IFRP
3DJHRI
)5HVHDUFK/DVWXSGDWHG$8*
